Sorry, this is not a mid-term 10-bagger. Nothing even approaching it. Remember that the market cap of this company is now 300 million. 300 million!
There is no way that Ropren sales can begin to justify a valuation like that. FDA approval is still years away, with a full Phase III trial to launch, or possible partnering (and associated revenue dilution).
Anyway, enjoy your holiday in Honkers. What a great spot. I hope you have some Solagran bubble bath handy to soothe your bottom line. I am appropriately jealous.
Add to My Watchlist
What is My Watchlist?
